-Reuters
Liminal Biosciences Q4 2022 Net Loss C$(4.2M)
Liminal Biosciences (NASDAQ:LMNL) will report on Q4 2022.
Related Posts
JP Morgan Reinstates Underweight on Intel, Lowers Price Target to $32
JP Morgan analyst Harlan Sur reinstates Intel (NASDAQ:INTC) with a Underweight and lowers the price target from $64 to $32.
Foresight Autonomous Inks Commercialization Agreement With Elbit
Foresight Autonomous Holdings Ltd (NASDAQ: FRSX) has
Western Alliance Bancorporation, Intuitive Surgical And Other Big Stocks Moving Higher In Wednesday’s Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Western Alliance Bancorporation (NYSE: WAL) shares jumped 15.4% to $37.50 in pre-market trading after the company reported better-than-expected Q1 earnings.